KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Receivables - Other: 2017-2024

Historic Receivables - Other for Moderna (MRNA) over the last 8 years, with Dec 2024 value amounting to $59.0 million.

  • Moderna's Receivables - Other fell 20.00% to $40.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.0 million, marking a year-over-year decrease of 20.00%. This contributed to the annual value of $59.0 million for FY2024, which is negligibly% changed negligibly from last year.
  • Moderna's Receivables - Other amounted to $59.0 million in FY2024, which was down 0.00% from $59.0 million recorded in FY2023.
  • Over the past 5 years, Moderna's Receivables - Other peaked at $61.0 million during FY2022, and registered a low of $10.0 million during FY2020.
  • Its 3-year average for Receivables - Other is $59.7 million, with a median of $59.0 million in 2024.
  • In the last 5 years, Moderna's Receivables - Other skyrocketed by 410.00% in 2021 and then decreased by 3.28% in 2023.
  • Yearly analysis of 5 years shows Moderna's Receivables - Other stood at $10.0 million in 2020, then soared by 410.00% to $51.0 million in 2021, then increased by 19.61% to $61.0 million in 2022, then decreased by 3.28% to $59.0 million in 2023, then remained steady at $59.0 million in 2024.